June 28, 2018 / 9:06 PM / 3 months ago

BRIEF-Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™

June 28 (Reuters) - Amgen Inc:

* AMGEN AND NOVARTIS PRESENT NEW DATA DEMONSTRATING LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF AIMOVIG™ (ERENUMAB-AOOE) IN PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE

* AMGEN - RESULTS FROM A ONE-YEAR STUDY IN CHRONIC MIGRAINE PATIENTS “REINFORCED” ESTABLISHED SAFETY AND EFFICACY PROFILE OF AIMOVIG IN LONG-TERM USE

* AMGEN INC - SAFETY RESULTS OF STUDY AFTER ONE YEAR WERE CONSISTENT WITH ESTABLISHED SAFETY PROFILE OF AIMOVIG IN PREVIOUS STUDIES

* AMGEN INC - EFFICACY DATA OF STUDY SHOWED SUSTAINED BENEFITS UP TO ONE YEAR

* AMGEN INC - AIMOVIG STUDY IS CONTINUING FOR UP TO FIVE YEARS OF TREATMENT Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below